Q-omics provides the consensus-scored KRT8P50 profile across patient tissues and cancer cell-line models. KRT8P50 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KRT8P50 is differentially expressed in 5, with the highest sampling consensus in HNSC. Additionally, KRT8P50 RNA expression shows 6,417 significant pathway-activity associations, with the highest sampling consensus in KIRC. Together, these results highlight KIRC, and HNSC as cancer lineages where KRT8P50 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRT8P50 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRT8P50 survival associations across molecular data types. KRT8P50 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRT8P50 RNA expression–survival associations across cancer types. High KRT8P50 expression shows unfavorable associations in KIRC, UVM, ACC and THCA, but favorable associations in MESO and BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for KRT8P50 RNA expression.
This table summarizes KRT8P50 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for KRT8P50. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRT8P50 shows lower tumor expression in COAD and higher tumor expression in HNSC, KIRC, BLCA and LUAD. The HNSC box plot shows higher KRT8P50 RNA expression in tumor versus normal tissue (log2 FC = +0.058, t-test p = .001).
This table shows molecular features associated with KRT8P50 in patient tissues and cancer cell lines. In patient samples, KRT8P50 shows the broadest associations at the RNA and protein expression levels, with KIRC recurring as the lineage with the largest associated feature set.
